Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Greta Ubiali
the Specific Bruton Tyrosine Kinase Inhibitor Acalabrutinib (ACP-196) Shows Favorable in Vitro Activity Against Chronic Lymphocytic Leukemia B Cells With CD20 Antibodies
Haematologica
Hematology
Related publications
Acalabrutinib (ACP-196): A Selective Second-Generation BTK Inhibitor
Journal of Hematology and Oncology
Cancer Research
Oncology
Hematology
Molecular Biology
Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Outcomes With Bruton Tyrosine Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Progression on Venetoclax
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia
Oncology and Therapy
Oncology
Resistance to ABT-199 Induced by Microenvironmental Signals in Chronic Lymphocytic Leukemia Can Be Counteracted by CD20 Antibodies or Kinase Inhibitors
Haematologica
Hematology
Activity of the Janus Kinase Inhibitor Ruxolitinib in Chronic Lymphocytic Leukemia: Results of a Phase II Trial
Haematologica
Hematology
Bruton Tyrosine Kinase Inhibitor ONO/GS-4059: From Bench to Bedside
Oncotarget
Oncology
Planned Pregnancy in Female Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy
Oncologist
Cancer Research
Medicine
Oncology
